Renal cell carcinoma with clear cell differentiation
Showing 1 - 25 of >10,000
Moesin Expression in Clear Cell Renal Cell Carcinoma
Completed
- Renal Cell Carcinoma
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- (no location specified)
Sep 20, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 18, 2023
Metastatic Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Metastatic Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 18, 2023
Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody
Recruiting
- Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
- AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally
-
Shanghai, Shanghai, ChinaShanghai Renji Hospital
Sep 12, 2023
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- +2 more
- (no location specified)
May 14, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 28, 2023
Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)
Available
- Clear Cell Renal Cell Carcinoma
- 89Zr-DFO-girentuximab
-
Los Angeles, CaliforniaUCLA
Oct 12, 2023
Multiomics Approach in Metastatic Clear Renal Cell Carcnoma
Recruiting
- Metastatic Clear Cell Renal Carcinoma
- CT scan
- Plasma collection
-
Milan, Mi, ItalyIstituto Tumori
Mar 13, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104)
Completed
- Clear Cell Renal Cell Carcinoma
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Feb 6, 2023
First-line Treatment of Non-clear Renal Cell Carcinoma Trial (Fruquintinib combined with Serplulimab)
Not yet recruiting
- First-line Treatment of Non-clear Renal Cell Carcinoma
- Fruquintinib combined with Serplulimab
- (no location specified)
Apr 16, 2023
Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)
Not yet recruiting
- Renal Cell Carcinoma
- Pucotenlimab Combined With Lenvatinib
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen University Cancer Center
Nov 10, 2023
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute
Not yet recruiting
- Advanced Clear Cell Renal Carcinoma (Ccrcc)
- Papillary Renal Cell Carcinoma (Prcc)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Non-clear Renal Cell Carcinoma Trial in Nanjing, Nanning (Toripalimab, Axitinib)
Recruiting
- Non-clear Renal Cell Carcinoma
-
Nanjing, Jiangsu, China
- +1 more
Mar 13, 2023
From Clear Cell Renal Cell Carcinoma
Recruiting
- Clear Cell Renal Cell Carcinoma
- Urinary sample
-
Saint-Étienne, FranceChu Saint-Etienne
Jul 13, 2022
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic Trial in Iowa City (Selenomethionine (SLM),
Recruiting
- Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma Metastatic
- Selenomethionine (SLM)
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics
Sep 19, 2022
Advanced Cancer, Clear Cell Renal Cell Carcinoma Trial in Houston (177Lu girentuximab, Nivolumab, Cabozantinib)
Not yet recruiting
- Advanced Cancer
- Clear Cell Renal Cell Carcinoma
- 177Lu girentuximab
- +3 more
-
Houston, TexasMD Anderson Cancer Center
Dec 15, 2022
Non-Clear Cell Renal Cell Carcinoma Trial in Duarte (XL092, Nivolumab, Sunitinib Malate)
Recruiting
- Non-Clear Cell Renal Cell Carcinoma
- XL092
- +2 more
-
Duarte, CaliforniaExelixis Clinical Site #1
Jan 13, 2023
Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1
Not yet recruiting
- Metastatic Clear Cell Renal Cell Carcinoma
- With Positive PSMA Expression at Tumor Sites
- 177Lu-PSMA-1 (radiopharmaceutical)
- (no location specified)
Sep 26, 2023
Clear Cell Renal Cell Carcinoma, Solid Tumors Trial (AB521)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- Solid Tumors
- (no location specified)
Sep 7, 2022